BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

...is also a founder of Clonatec, a French antibody company later acquired by OHF Group; RedCell...
BioCentury | Jun 22, 2001
Financial News

ConjuChem raises C$18.8 million

...of 3 million shares at C$6.25 in a follow-on. Four selling shareholders - BioCapital; Innovatech; RedCell...
BioCentury | Jun 4, 2001
Finance

Ebb & Flow

...deal managed by Yorkton; BMO Nesbitt Burns; and HSBC. Four selling shareholders - BioCapital; Innovatech; RedCell...
BioCentury | Jun 4, 2001
Finance

Ebb & Flow

...deal managed by Yorkton; BMO Nesbitt Burns; and HSBC. Four selling shareholders - BioCapital; Innovatech; RedCell...
BioCentury | May 30, 2001
Financial News

ConjuChem files for follow-on

...be underwritten by Yorkton; BMO Nesbitt Burns; and HSBC. Four selling shareholders - BioCapital; Innovatech; RedCell...
BioCentury | Jul 14, 1997
Emerging Company Profile

RedCell Canada Inc.

...Deep vein thrombosis, pain and cancer Clinical status: Preclinical Founded: 1997 with technology transfer from RedCell...
BioCentury | Jul 14, 1997
Emerging Company Profile

RedCell: Permanent bonds

...Emerging Company Profile RedCell: Permanent bonds Many drugs fail in development because they are rapidly metabolized...
...Others must be given at such high doses that they cause toxicities and side effects. RedCell Canada Inc....
...a longer duration of action, controlled distribution, decreased frequency of administration and increased compliance. Tethering RedCell's...
BioCentury | Jun 9, 1997
Company News

RedCell management update

...RedCell closes first tranche of private placement, B15) RedCell Canada Inc., Montreal, Quebec Business: Drug delivery Promoted: Alan...
BioCentury | Dec 16, 1996
Finance

Early (or late?) to the starting gate

...additional position of CEO, succeeding Eugene Zurlo, who will remain as chairman. . . . RedCell...
Items per page:
1 - 9 of 9
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

...is also a founder of Clonatec, a French antibody company later acquired by OHF Group; RedCell...
BioCentury | Jun 22, 2001
Financial News

ConjuChem raises C$18.8 million

...of 3 million shares at C$6.25 in a follow-on. Four selling shareholders - BioCapital; Innovatech; RedCell...
BioCentury | Jun 4, 2001
Finance

Ebb & Flow

...deal managed by Yorkton; BMO Nesbitt Burns; and HSBC. Four selling shareholders - BioCapital; Innovatech; RedCell...
BioCentury | Jun 4, 2001
Finance

Ebb & Flow

...deal managed by Yorkton; BMO Nesbitt Burns; and HSBC. Four selling shareholders - BioCapital; Innovatech; RedCell...
BioCentury | May 30, 2001
Financial News

ConjuChem files for follow-on

...be underwritten by Yorkton; BMO Nesbitt Burns; and HSBC. Four selling shareholders - BioCapital; Innovatech; RedCell...
BioCentury | Jul 14, 1997
Emerging Company Profile

RedCell Canada Inc.

...Deep vein thrombosis, pain and cancer Clinical status: Preclinical Founded: 1997 with technology transfer from RedCell...
BioCentury | Jul 14, 1997
Emerging Company Profile

RedCell: Permanent bonds

...Emerging Company Profile RedCell: Permanent bonds Many drugs fail in development because they are rapidly metabolized...
...Others must be given at such high doses that they cause toxicities and side effects. RedCell Canada Inc....
...a longer duration of action, controlled distribution, decreased frequency of administration and increased compliance. Tethering RedCell's...
BioCentury | Jun 9, 1997
Company News

RedCell management update

...RedCell closes first tranche of private placement, B15) RedCell Canada Inc., Montreal, Quebec Business: Drug delivery Promoted: Alan...
BioCentury | Dec 16, 1996
Finance

Early (or late?) to the starting gate

...additional position of CEO, succeeding Eugene Zurlo, who will remain as chairman. . . . RedCell...
Items per page:
1 - 9 of 9